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ABSTRACT 
The pyrimidine analog, 5-aza-2’-deoxycytidine (5-aza-dC) is a DNA methyltransferase inhibitor that triggers DNA de-
methylation leading to the reactivation of epigenetically silenced tumor suppressor genes. To understand the shift in 
gene expression which mediates the beneficial 5-aza-dC effects in leukemia, we have treated human myeloid derived 
leukemic cells with 5-aza-dC. Target genes were identified first in MV4-11 cells using a genome-wide gene expression 
profiling assay to detect differences in treated and untreated cells. From this analysis six genes were identified (HOXA4, 
HOXD4, HOXD8, HOXD12, CD9 and RGS2) as being significantly different expressed after treatment. To validate mi-
croarray data, we performed quantitative PCR on these genes from multiple leukemic cells. The results suggest that 
these genes are epigenetically regulated indicating that dysregulation of HOXA4, HOXD4, HOXD8, HOXD12, CD9 and 
RGS2 expression may play an important role in establishing the malignant phenotype in AML. 
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1. Introduction 
Aberrant DNA hypermethylation is a frequent event in 
malignancy which can result in the silencing of critical 
genes. For this reason, reversal of DNA methylation by 
methyltransferase inhibitors such as 5-aza-2’-deoxycy- 
tidine (5-aza-dC) may be a suitable therapeutic strategy 
to combat the dysregulation of the transcriptome due to 
aberrant epigenetic change. 
5-aza-dC is a well recognized activator of gene expres- 
sion as a result of decreased DNA methylation [1]. At pre- 
sent, 5-aza-dC has been approved by the FDA (Food and 
Drug Administration) as a standard care for the treatment 
of myelodysplastic syndrome (MDS) and acute myeloid 
leukemia (AML) [2]. As more is learned about the mecha- 
nism of hypomethylating agents, new roles are emerging 
for 5-aza-dC in combination therapy for MDS and other 
hematologic malignancies such as AML and chronic my- 
eloid leukemia [3,4]. 
AML is a genetically heterogeneous disease charac- 
terized by acquired somatic mutations in hematopoietic 
progenitor cells [5]. MDS describes a range of hemato- 
poietic disorders characterised by hyperproliferative bone 
marrow disease originating from abnormal multipotent 
progenitor cells that have a high risk of progressing to 
AML [6]. It has been reported that the use of the 5-aza- 
dC has significantly reduced the risk of progression to 
AML [7]. Aberrant DNA methylation can be observed in 
multiple functionally relevant genes including p15 
(CDKN2B) and is considered to play a significant role in 
development and progression to AML [8]. 
In this study, we found that the growth of leukemic 
cells, including MV4-11 cells, were inhibited after 5-aza- 
dC treatment suggesting this agent might be useful in re- 
versing the dysregulated transcriptome in MV4-11 cells. 
Whole genome expression profiling of the MV4-11 cells 
was performed to identify key targets associated with 
5-aza-dC treatment. Pathway prediction modelling re- 
vealed that multiple HOX genes, genes associated with 
Wnt-signalling pathway and those associated with cell dif- 
ferentiation were differentially expressed after 5-aza-dC 
treatment. From this experiment we selected six genes 
(HOXA4, HOXD4, HOXD8, HOXD12, CD9 and RGS2) 
on the basis of previous reports for further quantification 
in a series of human leukemia cell lines. 
2. Materials and Method 
2.1. Cells and Reagents 
MV4-11, Molm-14, HL-60, THP-1 (all AML derived cell 
lines) and Jurkat cells (acute lymphoblastic leukemia *Corresponding author. 
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derived) were originally purchased from ATCC (Ameri- 
can Type Culture Collection, Manassas, VA). The cells 
were cultured with RPMI-1640 media supplemented with 
10% FBS at 37˚C and 5% CO2. 5-aza-dC was purchased 
from Sigma-Aldrich (St. Louis, MO) and stored as a 10 
mM stock solution in PBS at –80˚C. They were diluted 
into cell culture media immediately prior to use. 
2.2. MTT Cell Proliferation Assay 
Cell proliferation assays using 3-4, 5-dimethylthiazol-2, 
5-diphenyltetrazolium (MTT) was performed as described 
previously [9]. Briefly, 50 µL media was divided into ali- 
quots into triplicate wells of 96-well plates for each 
5-aza-dC concentration. Cell suspension in media (50 µL) 
was added to each well (50 000 cells/well). Plates were 
incubated for 48 hours at 37˚C in 5% CO2, and then the 
MTT assay was performed according to the manufac- 
turer’s instructions (Roche, Indianapolis, IN). 
2.3. Gene Expression and Bioinformatic Analysis 
Total RNAs were obtained with TRIzol reagent (Invitro-
gen, Carlsbad, CA) from untreated MV4-11 cells, cells 
after 48hr treatment of 5-aza-dC (10 µM), and cells after 
48 hr release from the drug. The RNA was then hybrid-
ised to Illumina HumanRef-8 BeadChips to quantify gene 
expression levels. Data were first normalised in BeadStu- 
dio software (version 3.0) where values for each sample 
were subjected to cubic spline normalisation, and the 
t-test error model was applied to all samples. Data were 
then imported to GeneSpring Software (version 7.3.1, 
Agilent) and normalised to control for the variation in 
detection efficiency between gene signals. Using bioin- 
formatic prediction modelling (available at http://genome. 
ucsc.edu), we determined whether the influenced genes 
were associated with a CpG islands. Significant pathways 
were identified using the DAVID (Database for Annota- 
tion, Visualization and Integrated Discovery) Functional 
Annotation Tool and KEGG pathway analysis [10]. A 
modified Fisher Exact P-value and false discovery rates 
(Benjamini-Hochberg) were generated from the DAVID 
Functional Annotation Tool. 
2.4. Gene Expression Assay by Real-Time PCR 
Total RNA from MV4-11, Molm-14, HL-60, THP-1 and 
Jurkat cells was isolated for QPCR experiments using the 
RNeasy kit (Qiagen, Valencia, CA) according to the 
manufacturer’s instructions. Complementary DNA was 
produced from RNA by treatment with reverse transcript- 
tase using standard procedures. SYBR Green-based QPCR 
was performed using an ABI 7500 Real Time PCR Sys- 
tem and threshold cycle (Ct) results were calculated us- 
ing the manufacturer’s software (Applied Biosystems, 
Carlsbad, CA). We used Power SYBR Green PCR mas- 
ter mix from Applied Biosystems (Carlsbad, CA). Single 
time-point results were reported as a ΔCt (gene Ct – 
β-actin Ct), and fold differences were calculated as 2(−ΔCt) 
after statistical analysis. 
2.5. Methylation Specific PCR (MSP) 
Sodium bisulfite treatment of genomic DNA is known to 
convert unmethylated cytosines to uracil bases whereas 
methylated cytosines are protected from the conversion, 
thus enabling PCR amplification of CpG segments to be 
methylation specific [11]. Total genomic DNA were 
treated with sodium bisulfite using EpiTect Bisulfite Kit 
(Qiagen). PCR was carried out following the protocol 
written for methylation-specific PCR (MSP) by Licchesi 
and Herman [12]. Post-bisulfite-treated methylation- 
specific primers for the promoter region of CD9 was 
based on previously published MSP data, whereas prim- 
ers for post-bisulfite-treated unmethylation-specific for 
CD9 were custom designed using MethPrimer program 
[13,14] (Supplementary Table 1). 
3. Results 
3.1. 5-Aza-dC Induce Growth Inhibition of 
MV4-11 Cells 
Using the MTT proliferation assay, we first sought 
whether 5-aza-dC could induce cell growth inhibition in 
the leukemic cell lines. Cells were incubated for 48 hr in 
different concentrations of 5-aza-dC. Dose-dependent 
growth inhibition was observed in all leukemic cells (Fig- 
ure 1). Our findings indicate that 5-aza-dC is a weaker 
inducer of cell growth inhibition in Jurkat cells compared 
 
 
Figure 1. MTT cell proliferation assay. 5-aza-dC induces cell 
growth inhibition in various leukemic cells. MV4-11, Molm- 
14, THP-1, HL-60, and Jurkat cells were incubated with in- 
creasing concentrations of 5-aza-dC. The concentration of 
the drug was represented as a logarithmic scale in x-axis. 
The graph shows cell growth inhibition assessed by MTT 
assay after treatment of the drug for 48 hours (P < 0.01). 
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Table 1. Number of genes changed after exposure to 5-aza-dC in MV4-11 cells. 
Duration of Reactivation 
CpG +/– Always On Always Off Reactivated 
Short Term Long Term 
3× Up 3× Down 
Total 15,586 1275 1231 272 153 2311 2458 
CpG + 11,315 561 639 109 91 1332 1321 
CpG – 4271 714 592 163 62 979 1137 
CpG +, CpG island positive; CpG –, CpG island negative; Always On, genes are constantly expressed regardless of drug exposure; Always Off, gene expres-
sion was detected before and after treatment of drug; Reactivated, genes are not expressed in untreated control but expressed after drug treatment; Short Term, 
genes were reactivated after exposure to the drug and returned to the basal level of expression after cessation of treatment; Long Term, genes were reactivated 
after exposure to the drug and were continuously expressed after exposure cessation; 3× Up, genes were up-regulated greater than 3-fold after exposure to the 
drug; 3× Down, genes were down-regulated greater than 3-fold after exposure to the drug. 
 
to AML cell lines (HL-60, THP-1, MV4-11 and Molm- 
14). Furthermore, 5-aza-dC induces relatively greater 
growth inhibition in MV4-11 cells compared to the other 
AML cells tested (Figure 1). 
 
3.2. Influence of 5-Aza-dC on Gene Expression 
in MV4-11 Cells 
To better understand the role of 5-aza-dC, gene expres- 
sion profiles of MV4-11 cells treated with the drug were 
examined and compared to non-treated cells as described 
in the Methods section. We catalogued genes according 
to their pattern of gene expression changes and the num-
ber of genes is displayed in Table 1. Since many tumour 
suppressor genes are silenced by DNA hypermethylation, 
we first interrogated genes that were known to be silent 
in untreated control cells but expressed after exposure to 
5-aza-dC. These genes are referred to as “reactivated 
genes”. We next sought relative gene expression changes 
which were up-regulated (3-fold) or down-regulated (3- 
fold) after exposure to the drug. The number of genes 
associated with a CpG island is indicated below each 
group in Table 1. We found that the resulting gene ex- 
pression patterns following 5-aza-dC treatment are not 
always dependant on the presence of a CpG island. 
Figure 2. Gene expression changes in MV4-11 cells after 
5-aza-dC treatment. Hierarchical clustering of differentially 
expressed genes comparing untreated control (marked as 
“C”), after inhibition by 5-aza-dC (marked as “I”), and 
release from 5-aza-dC after treatment (marked as “R”) in 
MV4-11 cells. (A) Heatmap of expression levels of all clus- 
tered genes at three different status of the cells; (B) The 
clustered genes of which expression are relatively increased 
(2-fold or greater) after 5-aza-dC treatment and return to 
their basal level after release from 5-aza-dC are shown. 
 
We next performed KEGG pathway and Gene Ontol- 
ogy analysis from differentially expressed genes obtained 
from microarray data. This analysis revealed the most 
highly affected biological pathways relevant to disease 
specific reactivated genes and differentially expressed 
genes (Table 2). 
Unsupervised clustering analysis was performed from 
data generated from untreated MV4-11 cells, two days 
after exposure to 5-aza-dC, and two days after cessation 
of exposure in cell culture. Cells at each time point 
with/without drug display differential gene expression 
profiles (Figure 2A). In addition to Short Term re-acti- 
vated genes (Table 1), we determined which genes could 
be ‘reversibly’ affected by the drug. Gene entities were 
filtered based on the fold change and considered signifi- 
cant if it was greater than an absolute 2-fold change after 
drug treatment and returned to basal levels after drug 
withdrawal. Using the filtered gene entities, we generated 
a heatmap to display the corresponding genes (Figure 
2B). These genes are likely to be primarily affected by 
5-aza-dC in their expression. We found that several genes 
in the heatmap of Figure 2B have been previously reported 
to be involved in AML such as p15 (CDKN2B) [15].  
3.3. QPCR Confirmation of Microarray Data 
Validation of the microarray data was undertaken using a 
series of leukemic cell lines (HL-60, Jurkat, THP-1, 
Molm-14, and MV4-11 cells). On the basis of previous 
reports implicating a series of genes in leukemogenesis, 
six genes (HOXA4, HOXD4, HOXD8, HOXD12, CD9 
and RGS2) were selected for the further analysis by QPCR. 
We confirmed multiple HOX genes were reactivated 
greater than 50-fold after 5-aza-dC treatment in MV4-11 
cells. These four HOX genes were also highly reactivated 
in two of the AML cell lines, Molm-14 and THP-1 cells 
whereas in HL-60 and Jurkat cells a lower fold-change 
was observed except for the reactivation of HOXD4 in  
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Table 2. Summary of the most highly affected biological pathways which appear to be relevant to leukemic phenotype in 
MV4-11 cells after exposure to 5-aza-dC. Six genes selected for further study by QPCR are indicated in bold. 
Biological pathways Relevant genes Pattern of fold change 
Cell differentiation HOXA4, HOXC11, HOXD4, HOXD8, HOXD9, HOXD12 Reactivated 
Hematopoietic cell lineages CD1, CD3, CD7, CD8, CD9, CD11b, CD13, CD14, CD23, CD34, CD42, CD49, CD127, DNTT, IL6, CSF2 Up-regulated 
Wnt activators: DVL1, GSK-3β and TCF/LEF family (TCF7, 
TCF7L1, TCF15 and LEF1) Down-regulated 
Wnt-signalling pathway 
Wnt inhibitors: RGS2, WIF1, DKK3 Up-regulated 
 
Jurkat cells. We also confirmed relatively higher up- 
regulation of CD9 and RGS2 after 5-aza-dC treatment in 
MV4-11, Molm-14 and THP-1 cells compared to HL-60 
and Jurkat cells (Figure 3B). Taken together, gene ex- 
pression changes in our six selected genes from Table 2 
were highly correlated with microarray data (Figure 3). 
3.4. Methylation-Specific PCR (MSP) Revealed 
Hypermethylation of Promoter Region of 
CD9 at Base Line, and Relative Decrease in 
Methylation after 5-Aza-dC Treatment 
In order to validate the findings from microarray and 
QPCR and verify that the expression of the genes could be 
linked to gene promoter hypermethylation, we performed 
methylation-specific PCR (MSP) on MV4-11 cells. We 
selected CD9 for further analysis by MSP as it has been 
shown to be silenced by promoter hypermethylation in 
approximately 75% of cases of AML cases harbouring 
the t (8;21) translocation [16], although MV4-11 does not 
harbour t (8;21). Analysis of CD9 genomic architecture 
(using the “CpG island searcher” available at 
http://cpgislands.usc.edu/) revealed dense CpG islands. 
MSP analysis revealed strong methylation of the CD9 
promoter in MV4-11 cells (Figure 4), with reduced methy- 
lation in the same promoter region after 5-aza-dC treat- 
ment. Further, methylation of the CD9 promoter was re- 
versed and almost undetectable in MV4-11 cells after 
5-aza-dC treatment, whereas unmethylation-specific am- 
plicons were increased. Thus, this result suggests that the 
reversal of methylation of the CD9 promoter is the most 
likely mechanism of gene re-expression after 5-aza-dC 
treatment. 
4. Discussion 
The treatment of MV4-11 cells with the demethylating 
agent 5-aza-dC not surprisingly reactivated and up-regu- 
lated the expression of many genes. Here we identify the 
molecular pathways evoked in a leukemic cell line treated 
with 5-aza-dC to gain some insights of the events under- 
lying successful drug therapy. 
 
 
 
Figure 3. QPCR validates microarray data. The six genes 
(HOXA4, HOXD4, HOXD8, HOXD12, CD9 and RGS2) de-
scribed in Table 2 were analyzed by QPCR on total RNA 
from MV4-11, Molm-14, THP-1, HL-60 and Jurkat cells 
before and after 10 µM of 5-aza-dC treatment. We first 
obtained ΔCt (gene Ct—β-actin Ct) from Ct values of each 
gene for normalization and then ΔCt values were converted 
to relative gene expression using the 2-ΔCt method. Graph 
was presented to show relevant gene expression fold differ-
ences after treatment of the drug compared with untreated 
control (=1). The results show the mean and standard de-
viation for triplicate QPCR results from three independent 
experiments (P < 0.01). 
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Figure 4. Methylation-specific PCR demonstrates preferen-
tial promoter methylation of CD9 in MV4-11 cells and effect 
on DNA methylation after 5-aza-dC treatment. Genomic 
DNA from MV4-11 cells was obtained before and after 10 
µM of 5-aza-dC treatment for 48 hrs and then the purified 
DNA was treated with sodium bisulfite to specifically con- 
vert unmethylated cytosines to uracil. MSP was performed 
after purification of bisulfite-treated DNA using specific 
primers. PCR primers for anticipated post-bisulfite-me- 
thylated (M) and unmethylated (U) promoter sequences for 
CD9 was used to determine its methylation status. The an-
ticipated amplicon sizes for M and U are 153 bp and 110 bp 
respectively. L, 100 bp DNA ladder; N, non-template con-
trol; M, post-bisulfite methylated DNA specific primer used; 
U, post-bisulfite unmethylated DNA specific used. 
 
Our results revealed that several HOX genes are po- 
tentially suppressed by DNA hypermethylation in AML 
cells. Because over-expression of multiple HOX genes 
has been identified in both lymphoid and myeloid ma- 
lignancies, the potential mechanisms leading to increased 
HOX gene expression have been widely studied [17]. 
However, possible suppression of HOX genes by DNA 
hypermethylation is not clearly understood. Recently, ab- 
errant suppression of HOX genes by DNA hypermethyla-
tion in their promoter region have been found in various 
cancer models including leukemia [18]. Since all HOX 
genes in our reactivated gene list harbor CpG islands, our 
results suggest that multiple HOX genes may be silenced 
by possible DNA hypermethylation in AML cells and 
that their reactivation can be induced after exposure to 
5-aza-dC. In addition, HOXD8 and HOXD12 were mem- 
bers of our “Short Term” list in Table 1 and the heatmap 
in Figure 2B, suggesting these two genes are reversibly 
regulated by DNA methylation of their promoter region. 
Although many types of genes were reactivated or up- 
regulated by 5-aza-dC, intriguingly the pathways which 
are down-regulated by drug treatment also appear to be 
relevant. Several members of the Wnt-signalling pathway 
were down-regulated by greater than 3-fold after 5-aza-dC 
treatment (Table 2). It has been reported that Wnt path- 
way activation is associated with leukemic transforma- 
tion and adverse outcome in patients with AML [19,20]. 
While genetic alterations of the Wnt pathway are infre- 
quent in AML, inhibitors of this pathway appear to be 
silenced by promoter methylation [19,21]. We found that 
several major genes involved in the Wnt pathway in- 
cluding RGS2 were differentially expressed after expo-
sure to 5-aza-dC. Previous gene expression analyses in 
several myeloid cell lines showed induction of RGS2 
expression during granulocytic differentiation [22]. Fur- 
ther, it has been reported that epigenetic repression of 
RGS2 promotes prostate cancer cell growth [23]. Our 
microarray and QPCR data showed RGS2 is suppressed 
in leukemic cells and up-regulated after treatment of 
5-aza-dC suggesting that targeting Wnt-signaling may be 
valuable in treating leukemia. 
Among potential candidate tumor suppressor genes 
upregulated by 5-aza-dC, we identified CD9, a 24-kD 
transmembrane protein, belonging to the tetraspanin su- 
perfamily of surface molecules, which have been shown 
to play a role in normal megakaryocytic differentiation 
[24,25]. CD9 has been reported to be epigenetically sup- 
pressed in specific AML subsets [16] and multiple mye- 
loma [26], and myelodysplastic CD34+ cells [14]. Our 
study showed CD9 is suppressed in AML cells and was 
upregulated after 5-aza-dC treatment. Further, our MSP 
study confirmed that CD9 is one of the epigenetically 
silenced genes in MV4-11 cells by DNA hypermethyla- 
tion and that this can be reversed by hypomethylating 
reagent, 5-aza-dC. Through our global gene expression 
study, we have found that several important biological 
pathways are dysregulated in leukemic cells. These mul- 
tiple malignancies could potentially be utilized to better 
understand molecular events underlying successful drug 
therapy in leukemia. 
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